Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Radical cure of Plasmodium vivax and Plasmodium ovale malaria (FDA-approved),Prophylaxis of Plasmodium vivax relapse following treatment of acute infection
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primaquine is metabolized primarily by CYP1A2 and CYP3A4; also undergoes monoamine oxidase (MAO) metabolism. Metabolites include primaquine carboxy metabolite.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Approximately 90-95% bound to plasma proteins, primarily to albumin
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Apparent volume of distribution (Vd) approximately 2.5-3.5 L/kg, indicating extensive tissue distribution, including high concentrations in erythrocytes and liver, which is relevant for anti-relapse activity
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral bioavailability is approximately 96%, with peak plasma concentrations reached within 1-3 hours
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential accumulation.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Contraindicated in severe hepatic impairment; use with caution in mild-to-moderate impairment, reduce dose by 50% in Child-Pugh B, avoid in Child-Pugh C.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
0.3 mg/kg (base) orally once daily for 14 days; maximum 15 mg/day.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment, but monitor for hemolytic effects due to age-related decline in G6PD activity.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Primaquine can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Screen all patients for G6PD deficiency before prescribing.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Hemolytic anemia in G6PD deficiency – screen and monitor,Methemoglobinemia – monitor for signs especially in infants and G6PD-deficient patients,QT interval prolongation – use with caution with other QT-prolonging drugs,Hematologic toxicity – monitor CBC in prolonged therapy
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
G6PD deficiency (absolute),Concurrent use of quinacrine (due to increased toxicity),Pregnancy (safe alternative not established; risk of hemolysis in G6PD-deficient fetus),Lactation if infant is G6PD deficient
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Take with food to reduce gastrointestinal irritation. No specific food restrictions, but avoid alcohol as it may increase risk of adverse effects.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemia. Risk of hemolysis in G6PD-deficient fetuses; contraindicated in pregnancy except for severe malaria treatment when no alternatives exist.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Primaquine is excreted into breast milk in small amounts. M/P ratio not established. Risk of hemolysis in G6PD-deficient infants. Avoid breastfeeding in women with infant G6PD deficiency; use caution.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Pregnancy reduces primaquine exposure via increased clearance; however, due to teratogenicity and hemolytic risk, dosing adjustments are not recommended; alternative antimalarials preferred.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Primaquine is the only agent active against hypnozoites of Plasmodium vivax and P. ovale, preventing relapse. Screen for G6PD deficiency before use; hemolysis risk. Administer with food to reduce GI upset.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take with food to decrease stomach upset.,Report any signs of hemolysis: dark urine, yellow skin/eyes, fatigue.,Complete full course even if symptoms improve.,Avoid concurrent use with other drugs that cause hemolysis.,Inform your doctor of any history of favism or G6PD deficiency.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE vs ARAKODA, answered by our medical review team.
PRIMAQUINE is a Antimalarial that works by Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE is: 15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE is classified as Category D/X. Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemi. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.